Ausam Biotech to Ink Licensing Deal for Proteomic-Based Diagnostic | GenomeWeb

WASHINGTON, DC, Oct. 3 – Ausam Biotechnologies is set to strike a licensing deal in the current quarter with a pair of "major US pharmaceutical companies" for its proteomic-based kidney disease diagnostic, the company’s CEO told GenomeWeb on Wednesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.